| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ebfc8d66ac1303ed1e3e999d65aa236 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4743 |
| filingDate |
2005-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27c20db7f48aa6586a845ebbef82b482
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af471beaa0507d6ea5223444d967109e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8d08637c9d3119826bf6bb82b7a4fb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e8052bc127726921c3ebce0ba0ee39d |
| publicationDate |
2006-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2006069159-A1 |
| titleOfInvention |
Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
| abstract |
This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7879990-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009203655-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7968688-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007032548-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004092590-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011218242-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011097276-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009297440-A1 |
| priorityDate |
2002-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |